Prolocor and Slingshot Biosciences Announce Publication of ‘Assessing Prognosis by Quantifying FcγRIIa on Fixed Platelets’ in Bioanalysis
The Prolocor pFCG® test measures the expression of a specific protein on the platelet surface which this study demonstrates is a reliable prognostic tool to...
Prolocor Announces Appointment of Raymond Russo as Chief Commercial Officer
Prolocor, Inc., a healthcare startup developing an innovative precision diagnostic test with the potential to predict the risk of thrombosis by quantifying FcγRIIa (pFCG test),...
Prolocor to Present New Clinical Evidence at ACC 24 Supporting the Use of PLATELET FCɣRIIA (PFCG) as a Key Tool in Individualizing Dual Antiplatelet Therapy (DAPT)
Date April 6, 2024, Location Hall B4-5Abstract 1307-159 / 159ASSOCIATION BETWEEN PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA (PFCG) AND TREATMENT STRATEGY FOR MYOCARDIAL INFARCTION Prolocor, Inc.,...